Daraxonrasib doubles survival — a RAS‑targeting drug development breakthrough. Daraxonrasib doubled median survival versus ...

After shedding its oncology business just over a decade ago, GSK is building it back with a $10.6 billion deal.

A new drug targets RAS cancer-causing cells in the pancreas, nearly doubling survival rates in clinical trials. Here's how ...

BostonGene, developer of the leading AI model for tumor and immune biology, today announced it has been named a Diamond winner in the 2026 Pinnacle Awards for Healthcare. Recognized in the Innovator ...

By Bhanvi Satija and Yadarisa Shabong LONDON, June 9 (Reuters) - GSK has agreed to buy U.S.-listed cancer drug developer Nuvalent for $10.6 billion in its largest deal in more than a decade, marking a ...

GSK agrees to acquire Nuvalent for $10.6bn, strengthening its position in cancer drug development and expanding its oncology ...

A new daily pill called daraxonrasib is showing promise against advanced pancreatic cancer in a first-in-human trial of 168 ...

A new era in the treatment of deadly pancreatic cancer was heralded by scientists this week, thanks to research by the ...

Just 6 months into the job, GSK’s CEO is spearheading some big moves. The London-based pharma giant announced Tuesday that it ...

New research shows a medication called daraxonrasib is helping people with advanced pancreatic cancer live longer.

Cancer cells need large amounts of energy to survive and multiply. To produce that energy, they rely on structures inside the cell called mitochondria, often described as the cell's "powerhouse." ...

Advances in cancer research have led to an increasing number and variety of cancer therapies in the development pipeline, but there are concerns that traditional processes for drug development, ...